Emergent Biosolutions, Inc. (EBS): Price and Financial Metrics
GET POWR RATINGS... FREE!
EBS POWR Grades
- EBS scores best on the Value dimension, with a Value rank ahead of 99.43% of US stocks.
- The strongest trend for EBS is in Momentum, which has been heading down over the past 206 days.
- EBS ranks lowest in Momentum; there it ranks in the 7th percentile.
EBS Stock Summary
- EBS's current price/earnings ratio is 8.09, which is higher than only 11.78% of US stocks with positive earnings.
- In terms of twelve month growth in earnings before interest and taxes, Emergent BioSolutions Inc is reporting a growth rate of 314.37%; that's higher than 94.05% of US stocks.
- As for revenue growth, note that EBS's revenue has grown 53.99% over the past 12 months; that beats the revenue growth of 89.57% of US companies in our set.
- Stocks that are quantitatively similar to EBS, based on their financial statements, market capitalization, and price volatility, are DIOD, UCTT, ACLS, SSTK, and NAII.
- Visit EBS's SEC page to see the company's official filings. To visit the company's web site, go to www.emergentbiosolutions.com.
EBS Price Target
For more insight on analysts targets of EBS, see our EBS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $91.14 | Average Broker Recommendation | 1.61 (Moderate Buy) |
EBS Stock Price Chart Interactive Chart >
EBS Price/Volume Stats
| Current price | $62.00 | 52-week high | $137.61 |
| Prev. close | $58.50 | 52-week low | $55.07 |
| Day low | $59.41 | Volume | 489,000 |
| Day high | $62.18 | Avg. volume | 744,047 |
| 50-day MA | $76.51 | Dividend yield | N/A |
| 200-day MA | $96.22 | Market Cap | 3.32B |
Emergent Biosolutions, Inc. (EBS) Company Bio
Emergent BioSolutions is a biopharmaceutical company which develops, manufactures, and delivers a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. The company was founded in 1998 and is based in Gaithersburg, Maryland.
EBS Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $62.00 | $357.25 | 486% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Emergent BioSolutions Inc. To summarize, we found that Emergent BioSolutions Inc ranked in the 85th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 488.5% on a DCF basis. As for the metrics that stood out in our discounted cash flow analysis of Emergent BioSolutions Inc, consider:
- Emergent BioSolutions Inc's weighted average cost of capital (WACC) is 9%; for context, that number is higher than merely 13.14% of tickers in our DCF set.
- EBS's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than merely 13.14% of tickers in our DCF set.
- As a business, Emergent BioSolutions Inc experienced a tax rate of about 19% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than 79.87% of stocks generating free cash flow.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 474% |
| 1% | 480% |
| 2% | 486% |
| 3% | 491% |
| 4% | 497% |
| 5% | 503% |
Want more companies with a valuation profile/forecast similar to that of Emergent BioSolutions Inc? See CDNA, FGEN, ESMC, BMRN, and ALKS.
Latest EBS News From Around the Web
Below are the latest news stories about Emergent BioSolutions Inc that investors may wish to consider to help them evaluate EBS as an investment opportunity.
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Emergent BioSolutions Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – EBSNEW YORK, May 14, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Emergent BioSolutions Inc. (NYSE: EBS) between July 6, 2020 through March 31, 2021, inclusive (the “Class Period”), of the important June 18, 2021 lead plaintiff deadline. SO WHAT: If you purchased Emergent BioSolutions securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Emergent BioSolutions class action, go to http://www.rosenlegal.com/cases-register-2081.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action. A class actio... |
EBS ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 18, 2021 in the Class Action Filed on Behalf of Emergent Biosolutions Inc. Limited ShareholdersNew York, New York--(Newsfile Corp. - May 14, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Emergent Biosolutions Inc. (NYSE: EBS) alleging that the Company violated federal securities laws.Class Period: July 6, 2020 and March 31, 2021Lead Plaintiff Deadline: June 18, 2021Learn more about your recoverable losses in EBS:http://www.kleinstocklaw.com/pslra-1/emergent-biosolutions-inc-loss-submission-form?id=15890&from=5The filed complaint alleges that Emergent Biosolutions Inc. made materially false and/or misleading statements ... |
CLASS ACTION UPDATE for EBS, GOEV, SOS: HAGENS BERMAN Updates Investors on Securities Class Actions, Advises Investors with Losses to Contact the Firm NowSAN FRANCISCO, CA / ACCESSWIRE / May 14, 2021 / Hagens Berman updates investors in the following publicly-traded companies and urges investors who have suffered significant losses to contact the firm. Further details about the cases, including important upcoming deadlines, can be found at the links provided. |
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Emergent Biosolutions Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - EBSNew York, New York--(Newsfile Corp. - May 14, 2021) - To: All persons or entities who purchased or otherwise acquired securities of Emergent Biosolutions Inc. ("Emergent Bio") (NYSE: EBS) between July 6, 2020 and March 31, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of Maryland. To get more information go to:https://www.zlk.com/pslra-1/emergent-biosolutions-inc-loss-submission-form?prid=15880&wire=5or contact Joseph E. Levi, Esq. either via ... |
DEADLINE ALERT for FUV, EBS, ACAD, and CCIV: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of ShareholdersLOS ANGELES, May 14, 2021 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to [email protected] Arcimoto, Inc. (NASDAQ: FUV)Class Period: February 14, 2018 – March 22, 2021Lead Plaintiff Deadline: June 18, 2021 The complaint filed alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse fact... |
EBS Price Returns
| 1-mo | -20.14% |
| 3-mo | N/A |
| 6-mo | -27.32% |
| 1-year | -25.61% |
| 3-year | 22.43% |
| 5-year | 50.67% |
| YTD | -30.80% |
| 2020 | 66.08% |
| 2019 | -8.99% |
| 2018 | 27.57% |
| 2017 | 41.50% |
| 2016 | -17.92% |
Continue Researching EBS
Want to do more research on Emergent BioSolutions Inc's stock and its price? Try the links below:Emergent BioSolutions Inc (EBS) Stock Price | Nasdaq
Emergent BioSolutions Inc (EBS) Stock Quote, History and News - Yahoo Finance
Emergent BioSolutions Inc (EBS) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...